• Value Pillars
  • Supplier Diversity
  • Supplier Standards
  • What We Do
  • How We Hire
  • Job Spotlight
  • Employee Benefits
  • Students
  • Innovation
  • Career Stories
  • Corporate Governance
  • Quarterly Results
  • SEC Filings
  • News Releases
  • Pharmaceutical Pipeline
  • 2019 Janssen Transparency Report
  • 2019 Health for Humanity Report
  • Stock Information
  • Webcasts & Presentations
  • Investor Fact Sheet
  • Global Community Impact
  • Global Public Health
  • Global Environmental Health
  • Sustainability Reporting
  • Follow Us
  • As the European Commission grants Marketing Authorization for the company's Ebola vaccine regimen—a key step towards enabling broader access to it for the people who need it most—we share top facts about the vaccine for the deadly virus.
    Johnson & Johnson's Chief Communication Officer Michael Sneed sits down to have a frank discussion about what we need to do to help build a more equitable healthcare system—and society.
    From scientists working on a potential vaccine to medically trained employees who mobilized to the front lines to help treat patients, these men and women share what most resonates for them about the unique and devastating virus, both professionally and personally.
    Doctors, nurses and other healthcare professionals are working tirelessly to treat patients infected with the novel coronavirus. To bolster their heroic efforts, the company committed $50 million to help organizations dedicated to helping them.
    The heart condition affects up to six million Americans, and raises the risk of stroke five-fold. One patient describes what it was like to learn she had atrial fibrillation—and the unexpected positive impact it has had on her life.
    Imagine being a researcher who is staring down not only a highly infectious virus, but one that's caused the first global pandemic in more than 100 years. Meet Johnson & Johnson's Hanneke Schuitemaker, Ph.D.
    30 mothers. Their 31 children. Ten years ago, Kimberly Capone, Ph.D., set out to study the ways the microorganisms living on their skin evolved over time—and what that could mean for our understanding of skin health. She shares the groundbreaking results.
    Live Video Series
    The Road to a Vaccine
    "The Road to a Vaccine" is a groundbreaking eight-episode series that explores the COVID-19 crisis and the urgent global efforts to develop a vaccine candidate to help fight the pandemic.
    Episode 8
    What Two Renowned Virus Hunters Want Us to Know About COVID-19
    Virologist Peter Piot, M.D., Ph.D., talks with Paul Stoffels, M.D., about what it was like to personally battle COVID-19. World renowned expert Cato Laurencin, M.D., Ph.D., discusses why racism is a public health crisis. Plus, other coronavirus news.
    Episode 1
    Join host Lisa Ling as she interviews scientists and healthcare workers about how vaccines work, the impact of the COVID-19 pandemic and what’s being done globally to create a novel coronavirus vaccine.
    How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There
    How a COVID-19 Vaccine Might Work. Plus, How Quickly We Could Get There
    Episode 2
    Three leading scientists who have been on the frontlines of Zika, malaria and HIV give you the inside scoop on vaccine development and the process of going from lab to clinic.
    What it Takes to Create a Coronavirus Vaccine in Record Time
    What it Takes to Create a Coronavirus Vaccine in Record Time
    Episode 3
    Lisa Ling interviews National Academies member and University Professor at the University of Connecticut, Cato Laurencin, M.D., Ph.D., to learn what his new coronavirus study reveals. Plus, what’s needed to mass-produce a vaccine and what we’ve learned from other outbreaks.
    Why is COVID-19 Hitting Minority Communities So Hard?
    Why is COVID-19 Hitting Minority Communities So Hard?
    Episode 4
    This week we hear from two ER doctors about what they’ve learned from caring for COVID-19 patients. A renowned epidemiologist shares why testing is so important. A Nigerian doctor who recovered from Ebola herself talks about how fighting this outbreak is different. Plus, a leading scientist talks about how long vaccine immunity could last.
    What Doctors On The Front Lines of COVID-19 Are Now Saying About the Virus
    What Doctors On The Front Lines of COVID-19 Are Now Saying About the Virus
    Episode 5
    Two nurses—one on the front lines in the ICU, and one leading the charge to advocate for her profession—talk about what caring for patients, and each other, really means right now. An activist talks about recovering from the virus and a scientist shares the challenges of creating a vaccine for clinical. Plus, Arianna Huffington and Husseini K. Manji, MD, FRCPC, discuss the other COVID-19 crisis: how it's impacting mental health.
    How Nurses Are Battling the COVID-19 Pandemic
    How Nurses Are Battling the COVID-19 Pandemic
    Episode 6
    Lisa Ling speaks with the Chair of the Coalition for Epidemic Preparedness Innovations, the head of Global Public Affairs at UPS, and other experts about what it will take to get a vaccine to the people who need it. Plus, a young Nigerian activist on her outreach efforts.
    How the Global Community is Coming Together to Battle COVID-19
    How the Global Community is Coming Together to Battle COVID-19
    Episode 7
    In Episode 7, Lisa Ling speaks with Johnson & Johnson Chief Scientific Officer Paul Stoffels, M.D., about important advances being made in vaccine development. Former FDA Commissioner Mark McClellan, M.D., Ph.D., discusses what reopening could look like and global health leader Jonathan Quick, M.D., MPH, shares why he believes testing is critical to help manage this pandemic.
    What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
    What Our “New Normal” Might Look Like Until We Get a COVID-19 Vaccine
    Episode 8
    Virologist Peter Piot, M.D., Ph.D., talks with Paul Stoffels, M.D., about what it was like to personally battle COVID-19. World renowned expert Cato Laurencin, M.D., Ph.D., discusses why racism is a public health crisis. Plus, other coronavirus news.
  • Fact
    3.3%. That’s the increase in worldwide sales that Johnson & Johnson reported in the 1st quarter of 2020.
  • Recent Johnson & Johnson Initiatives in the Spotlight

    Learn more about the company’s latest groundbreaking programs, game-changing innovations and global partnerships—all aimed at helping change the trajectory of health for humanity.
    This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
    You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
    Continue